The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Valcivir     2-[(2-amino-6-oxo-3H-purin- 9...

Synonyms: Zelitrex, Talavir, Valtrex, ValACV, Virval, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Zelitrex


Psychiatry related information on Zelitrex


High impact information on Zelitrex


Chemical compound and disease context of Zelitrex


Biological context of Zelitrex


Anatomical context of Zelitrex


Associations of Zelitrex with other chemical compounds


Gene context of Zelitrex


Analytical, diagnostic and therapeutic context of Zelitrex


  1. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Lowance, D., Neumayer, H.H., Legendre, C.M., Squifflet, J.P., Kovarik, J., Brennan, P.J., Norman, D., Mendez, R., Keating, M.R., Coggon, G.L., Crisp, A., Lee, I.C. N. Engl. J. Med. (1999) [Pubmed]
  2. Valacyclovir to prevent cytomegalovirus disease after renal transplantation. Shapiro, M.E., Abrams, J.M. N. Engl. J. Med. (1999) [Pubmed]
  3. Varicella-zoster virus. Arvin, A.M. Clin. Microbiol. Rev. (1996) [Pubmed]
  4. Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma. Battegay, M., Berger, C., Rochlitz, C., Hurwitz, N., Hirsch, H.H., De Geyter, C., Haque, T., Nadal, D. Antivir. Ther. (Lond.) (2004) [Pubmed]
  5. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group. Spruance, S.L., Tyring, S.K., DeGregorio, B., Miller, C., Beutner, K. Arch. Intern. Med. (1996) [Pubmed]
  6. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older. Arora, A., Mendoza, N., Brantley, J., Yates, B., Dix, L., Tyring, S. J. Infect. Dis. (2008) [Pubmed]
  7. Once-daily valacyclovir hydrochloride for suppression of recurrent genital herpes. Baker, D.A., Blythe, J.G., Miller, J.M. Obstetrics and gynecology. (1999) [Pubmed]
  8. Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C.A., Crisp, A., Webster, A. Blood (2002) [Pubmed]
  9. Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. Kim, I., Chu, X.Y., Kim, S., Provoda, C.J., Lee, K.D., Amidon, G.L. J. Biol. Chem. (2003) [Pubmed]
  10. Purification and characterization of a rat liver enzyme that hydrolyzes valaciclovir, the L-valyl ester prodrug of acyclovir. Burnette, T.C., Harrington, J.A., Reardon, J.E., Merrill, B.M., de Miranda, P. J. Biol. Chem. (1995) [Pubmed]
  11. The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice. LeBlanc, R.A., Pesnicak, L., Godleski, M., Straus, S.E. J. Infect. Dis. (1999) [Pubmed]
  12. Valaciclovir: a review of its use in the management of herpes zoster. Ormrod, D., Goa, K. Drugs (2000) [Pubmed]
  13. A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. Feinberg, J.E., Hurwitz, S., Cooper, D., Sattler, F.R., MacGregor, R.R., Powderly, W., Holland, G.N., Griffiths, P.D., Pollard, R.B., Youle, M., Gill, M.J., Holland, F.J., Power, M.E., Owens, S., Coakley, D., Fry, J., Jacobson, M.A. J. Infect. Dis. (1998) [Pubmed]
  14. Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5. Hasenburg, A., Fischer, D.C., Tong, X.W., Rojas-Martinez, A., Kaufman, R.H., Ramzy, I., Kohlberger, P., Orlowska-Volk, M., Aguilar-Cordova, E., Kieback, D.G. J. Soc. Gynecol. Investig. (2002) [Pubmed]
  15. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled, multicentre trial. Engström, M., Berg, T., Stjernquist-Desatnik, A., Axelsson, S., Pitkäranta, A., Hultcrantz, M., Kanerva, M., Hanner, P., Jonsson, L. Lancet. Neurol (2008) [Pubmed]
  16. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Weller, S., Blum, M.R., Doucette, M., Burnette, T., Cederberg, D.M., de Miranda, P., Smiley, M.L. Clin. Pharmacol. Ther. (1993) [Pubmed]
  17. Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor. Phan, D.D., Chin-Hong, P., Lin, E.T., Anderle, P., Sadee, W., Guglielmo, B.J. Antimicrob. Agents Chemother. (2003) [Pubmed]
  18. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Lycke, J., Malmeström, C., Ståhle, L. Antimicrob. Agents Chemother. (2003) [Pubmed]
  19. Prophylaxis against herpesvirus infections in transplant recipients. Ljungman, P. Drugs (2001) [Pubmed]
  20. Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. Walling, D.M., Flaitz, C.M., Nichols, C.M., Hudnall, S.D., Adler-Storthz, K. J. Infect. Dis. (2001) [Pubmed]
  21. Persistence of infectious herpes simplex virus type 2 in the nervous system in mice after antiviral chemotherapy. Thackray, A.M., Field, H.J. Antimicrob. Agents Chemother. (2000) [Pubmed]
  22. Epstein-Barr virus replication in oral hairy leukoplakia: response, persistence, and resistance to treatment with valacyclovir. Walling, D.M., Flaitz, C.M., Nichols, C.M. J. Infect. Dis. (2003) [Pubmed]
  23. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection. Reischig, T., Jindra, P., Mares, J., Cechura, M., Svecová, M., Hes, O., Opatrný, K., Treska, V. Transplantation (2005) [Pubmed]
  24. Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. Gimenez, F., Foeillet, E., Bourdon, O., Weller, S., Garret, C., Bidault, R., Singlas, E. Clinical pharmacokinetics. (2004) [Pubmed]
  25. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Wald, A., Selke, S., Warren, T., Aoki, F.Y., Sacks, S., Diaz-Mitoma, F., Corey, L. Sexually transmitted diseases. (2006) [Pubmed]
  26. Delineation of human peptide transporter 1 (hPepT1)-mediated uptake and transport of substrates with varying transporter affinities utilizing stably transfected hPepT1/Madin-Darby canine kidney clones and Caco-2 cells. Bhardwaj, R.K., Herrera-Ruiz, D., Sinko, P.J., Gudmundsson, O.S., Knipp, G. J. Pharmacol. Exp. Ther. (2005) [Pubmed]
  27. Pharmacokinetics of valaciclovir. MacDougall, C., Guglielmo, B.J. J. Antimicrob. Chemother. (2004) [Pubmed]
  28. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Kobayashi, Y., Yamamoto, T., Cha, S.H., Sekine, T., Endou, H. J. Pharmacol. Exp. Ther. (2002) [Pubmed]
  29. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Ganapathy, M.E., Huang, W., Wang, H., Ganapathy, V., Leibach, F.H. Biochem. Biophys. Res. Commun. (1998) [Pubmed]
  30. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Hantz, S., Michel, D., Fillet, A.M., Guigonis, V., Champier, G., Mazeron, M.C., Bensman, A., Denis, F., Mertens, T., Dehee, A., Alain, S. Antimicrob. Agents Chemother. (2005) [Pubmed]
  31. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir. Tyring, S.K., Baker, D., Snowden, W. J. Infect. Dis. (2002) [Pubmed]
  32. Valaciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpesvirus infections. Perry, C.M., Faulds, D. Drugs (1996) [Pubmed]
  33. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. Gupta, R., Wald, A., Krantz, E., Selke, S., Warren, T., Vargas-Cortes, M., Miller, G., Corey, L. J. Infect. Dis. (2004) [Pubmed]
WikiGenes - Universities